Rhumbline Advisers Purchases 32,790 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Rhumbline Advisers lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 7.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 452,517 shares of the medical research company's stock after purchasing an additional 32,790 shares during the quarter. Rhumbline Advisers owned 0.26% of IQVIA worth $79,779,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. GKV Capital Management Co. Inc. bought a new stake in IQVIA during the 4th quarter worth approximately $39,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA in the 4th quarter worth $44,000. Zions Bancorporation N.A. grew its position in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares during the period. SBI Securities Co. Ltd. acquired a new stake in IQVIA in the fourth quarter worth $60,000. Finally, Thematics Asset Management bought a new position in IQVIA during the fourth quarter worth about $76,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Trading Down 0.5%

NYSE IQV traded down $0.68 during trading hours on Thursday, reaching $147.22. The company's stock had a trading volume of 3,262,422 shares, compared to its average volume of 1,590,268. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market cap of $25.47 billion, a P/E ratio of 19.63, a P/E/G ratio of 1.99 and a beta of 1.28. The firm has a fifty day simple moving average of $148.65 and a 200-day simple moving average of $179.70.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business's quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.54 earnings per share. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of research analyst reports. Citigroup restated a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Truist Financial cut their price objective on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. Barclays lowered their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.